Loading data for ABCL — first visit, this takes a few seconds.

提醒

AbCellera Biologics Inc. (ABCL)

NasdaqGS: ABCL · 即時價格 · USD

11.35

-1.05 (-8.47%)

收盤價： Aug 28, 2026, 3:59 PM

11.37

+0.20%

盤後: 7:59 PM

股價、關鍵數字和最新消息，都在這一頁。

-8.47% (1D)

買價	8.82
市值	3.68B
營收 (ttm)	66.17M
淨利（ttm）	-164.66M
	1.19
	-0.49
	n/a
	-15.87
P/B (ttm)	3.88
P/S (ttm)	55.58
財報日期	Nov 5, 2026

賣價	14.51
成交量	5,837,003
20 日平均成交量	7,931,387
開盤價	12.30
前收盤價	12.40
當日區間	11.26 - 12.35
52 週範圍	2.75 - 12.58
分析師	n/a
目標價	n/a
股利	n/a
除息日	n/a

關於 ABCL

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, su...

[閱讀更多]

產業 Biotechnology

類股 Healthcare

IPO 日期 Dec 11, 2020

員工 562

證券交易所 NasdaqGS

股票代號 ABCL

網站 https://www.abcellera.com

完整的公司簡介

財務表現

AbCellera Biologics 在 2025 年的營收為 75.13M，較前一年的 28.83M 增加 160.56%。淨利為 -146.41M，較前期減少 -10.1%。

財務報表

財報驚奇

AbCellera Biologics 已於 Aug 5, 2026 公布季度財報：

營收為 $4.05M 低於預期 $0, 年增 -76.29% 下滑.
每股盈餘為 -0.18 低於預期 -0.02, 年增 -50.00% 下滑.

下次財報發布

AbCellera Biologics Inc. 的下次財報預計於 Nov 5, 2026, 盤中。
分析師預估營收 ... 升級

新聞動態

2 週前 · Insider Monkey

AbCellera (ABCL) Soars 64% as Drug Candidate Holds Huge Market Opportunity

AbCellera Biologics (NASDAQ:ABCL) has seen its stock price jump by 64 percent week-on-week, making it the top-performing mid-cap stock in the US market last week, thanks to strong clinical trial resul...

2 週前 · Insider Monkey

Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?

On July 29, AbCellera Biologics Inc. (NASDAQ:ABCL) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced a strategic collaboration to research, develop, and commercialize multispecific T-cel...

2 週前 · MT Newswires

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Amid Producer Inflation Data Release

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.2%, and the actively tra

2 週前 · Motley Fool

AbCellera (ABCL) Q2 2026 Earnings Call Transcript

Lead program ABCL635 Phase 2 enrollment complete with data expected in August.

2 週前 · Simply Wall St.

AbCellera Biologics (ABCL) Is Up 60.3% After Strong Phase 2 Menopause Data For ABCL635 - Has The Bull Case Changed?

AbCellera Biologics recently reported that its investigational antibody ABCL635 achieved statistically significant Phase 2 results, with a single 600 mg subcutaneous dose reducing both the frequency a...

第 1 頁，共 2 頁

AbCellera Biologics Inc. (ABCL)